Rheumatoid arthritis is a chronic autoimmune disease characterised by joint synovial inflammation, along with cartilage and bone tissue destruction. Dendrimers can offer new opportunities as drug delivery systems of molecules of interest. Herein we aimed to develop poly(amidoamine) dendrimers (PAMAM), functionalised with chondroitin sulphate (CS), lined with anti-TNF α antibodies (Abs) to provide anti-inflammatory properties. Physicochemical characterisation demonstrated that anti-TNFα Abs-CS/PAMAM dendrimer NPs were successfully produced. The in vitro studies revealed that CS/PAMAM dendrimer NPs did not affect the ATDC5 and THP-1 cell lines' metabolic activity and proliferation, presenting good cytocompatibility and hemocompatibility. Moreover, anti-TNFα Abs-CS/PAMAM dendrimer NPs showed suitable TNF α capture capacity, making them appealing for new immunotherapies in RA patients.

类风湿关节炎是一种慢性自身免疫性疾病，其特征是关节滑膜炎症，软骨和骨组织破坏。树状大分子作为目标分子的药物递送系统可以提供新的机会。在本文中，我们旨在开发用硫酸软骨素（CS）功能化，内衬抗TNFα抗体（Abs）的聚（酰胺胺）树状聚合物（PAMAM），以提供抗炎特性。理化特性表明，成功生产了抗TNFαAbs-CS / PAMAM树状聚合物NP。在体外研究表明，CS / PAMAM树状大分子NP不会影响ATDC5和THP-1细胞系的代谢活性和增殖，表现出良好的细胞相容性和血液相容性。此外，抗TNFαAbs-CS / PAMAM树状聚合物NPs显示出合适的TNFα捕获能力，使其在RA患者中吸引了新的免疫疗法。